-
UCB Announces U.S. FDA Approval for Zilbrysq (zilucoplan) Autoinjector Self-administration for Adults Living with Generalized Myasthenia Gravis
Brussels, Belgium and Atlanta, Georgia – October 16, 2026 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered… Source: Read More
-
Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform
Verix’s patented Tovana™ platform and its full team join Trinity, extending TrinityEDGE™ from what commercial teams know into what they do next WALTHAM, Mass., Oct. 20, 2026 /PRNewswire/ — Trinity, the leader in integrating human and artificial intelligence for life sciences… Source: Read More
-
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn’s Disease
NYSE: $ABBV NORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic… Source: Read More
-
Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
NYSE: $GSK Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite… Source: Read More
-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
Nanjing, China — October 12, 2026 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track… Source: Read More
-
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
South San Francisco, CA — October 15, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of… Source: Read More
-
Blood-Pressure Drug Losartan May Activate Health-Promoting Brown Fat
October 14, 2026 — In a National Institutes of Health (NIH)-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue activity in mice, enhancing their metabolism… Source: Read More
-
Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City
JUPITER, Fla., Oct. 16, 2026 /PRNewswire/ — Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New… Source: Read More
-
Westcove Advises Clinical Research of West Florida in its Partnership with Fengate Private Equity
LOS ANGELES, Oct. 16, 2026 /PRNewswire/ — Westcove Partners, LLC (“Westcove”), a highly specialized investment bank, announced that it acted as the exclusive financial advisor to Clinical Research of West Florida (“CRWF”) in its partnership with Fengate Private Equity, a division of… Source: Read More
-
FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder
September 29, 2026 — Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Lamlique&trade… Source: Read More
-
Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition
CAMBRIDGE, Mass., Oct. 15, 2026 /PRNewswire/ — Marengo Therapeutics Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced that the U.S. Food and… Source: Read More
-
The Future of Oncology: Cancer Diagnostics Market Poised to Hit $41.5 Billion by 2031
A Significant Shift in Healthcare The landscape of oncology is undergoing a profound transformation. According to recent findings from Wissen Research, the global cancer diagnostics market is on a trajectory of rapid expansion. Valued significantly today, the industry is projected to reach an impressive US $41.5 billion by 2031. Growth Drivers This projected growth reflects…
-
Atomvie Global Radiopharma and Jubilant Radiopharma Announce Strategic Partnership for Clinical Logistics
Strengthening the Future of Radiopharmaceutical Distribution In a significant move for the field of nuclear medicine, Atomvie Global Radiopharma has officially announced a strategic partnership with Jubilant Radiopharma. This collaboration is designed to optimize and expand the logistics and distribution network for clinical trials, addressing the complex supply chain challenges inherent in radiopharmaceutical development. Strategic…
-
Merck Announces Promising One-Year Results for Remigromig in Phase 2b/3 Brunello Study
NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…
-
Bold Therapeutics Hits Key Milestone in Phase 2 Trial for Metastatic Colorectal Cancer
A Significant Step Forward in Cancer Research Bold Therapeutics has officially announced a major achievement in its clinical development program: the company has reached the enrollment midpoint for its randomized Phase 2 clinical trial evaluating BOLD-100. This trial is specifically focused on patients battling second-line metastatic colorectal cancer (mCRC). Understanding the Potential of BOLD-100 BOLD-100…
-
Promising Progress: Efzimfotase Alfa Shows Improvement in Hypophosphatasia Treatment
A New Frontier in HPP Research Recent clinical trial findings have shed light on a potential breakthrough for patients living with hypophosphatasia (HPP), a rare and serious genetic disorder. Data recently released regarding efzimfotase alfa—an investigational enzyme replacement therapy—suggests a meaningful step forward in managing the physical limitations associated with this condition. Understanding the Clinical…
-
New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment
NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…
-
NICHOLSMD Brings Advanced Hair Restoration to Greenwich with ACORN-YOU Secretome
Revolutionizing Hair Health in Greenwich NICHOLSMD of Greenwich has officially announced the launch of ACORN-YOU Secretome, a groundbreaking treatment now available at The Hair Lab. This innovative therapy represents a significant shift in regenerative aesthetics, focusing on the power of secretome technology to address hair thinning and loss. What is ACORN-YOU Secretome? The ACORN-YOU Secretome…
-
New Hope on the Horizon: Bristol Myers Squibb Launches Phase 3 ALOFT Trial for IPF
NYSE: $BMY A New Frontier in Pulmonary Research The fight against Idiopathic Pulmonary Fibrosis (IPF), a progressive and chronic lung disease, has reached a significant milestone. Bristol Myers Squibb has officially announced the initiation of the Phase 3 ALOFT clinical trial, a critical step in evaluating the efficacy and safety of a potential new treatment:…
-
Paradigm Therapeutics Recognized Again: SD-101 Nominated for Prestigious Prix Galien USA 2026
A Repeat Achievement in Biotech Innovation Paradigm Therapeutics Inc. has once again solidified its position at the forefront of medical innovation. For the second consecutive year, the company has been nominated for the highly esteemed Prix Galien USA 2026. This recognition highlights the company’s commitment to pushing the boundaries of dermatological science. The Innovation: SD-101…
-
A New Hope for Alopecia Areata: FDA Breakthrough Designation for Cinainu
A Major Milestone in Hair Loss Treatment There is promising news for individuals living with alopecia areata. Legacy Healthcare has officially announced that their investigational drug, Cinainu, has received FDA Breakthrough Therapy Designation for the treatment of alopecia areata in adults. Understanding the Significance The FDA’s Breakthrough Therapy Designation is a vital step in the…
-
FDA Approves Tecentriq Combination as Adjuvant Therapy for Specific Colon Cancer
A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…
-
SK Life Science Supports SUDEP Awareness Efforts Through Partnership with CURE Epilepsy and The Cameron Boyce Foundation
SK Life Science to Match Donations Up to $10,000 to Advance SUDEP Research, Awareness, and Education Release Highlights: SK Life Science to match donations to CURE Epilepsy up to $10,000 Supporting SUDEP awareness efforts with CURE Epilepsy and The Cameron Boyce Foundation Raising… Source: Read More